Bain Capital Life Sciences Investors’s Cabaletta Bio CABA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.6M	Buy	17,241,445 +7,564,320	+78%	+$24.9M	3.19%	10
2026 Q1	$26M	Hold	9,677,125	–	–	2.35%	11
2025 Q4	$21.2M	Hold	9,677,125	–	–	1.62%	13
2025 Q3	$22.6M	Hold	9,677,125	–	–	1.5%	12
2025 Q2	$14.7M	Buy	9,677,125 +6,916,237	+251%	+$10.8M	1.84%	12
2025 Q1	$3.82M	Hold	2,760,888	–	–	0.57%	16
2024 Q4	$6.27M	Hold	2,760,888	–	–	0.74%	18
2024 Q3	$13M	Buy	2,760,888 +1,110,924	+67%	+$6.43M	1.36%	12
2024 Q2	$12.3M	Buy	1,649,964 +32,600	+2%	+$400K	1.36%	14
2024 Q1	$27.6M	Sell	1,617,364 -382,636	-19%	-$8.21M	2.22%	12
2023 Q4	$45.4M	Hold	2,000,000	–	–	4.35%	7
2023 Q3	$30.4M	Hold	2,000,000	–	–	3.4%	10
2023 Q2	$25.8M	Buy	+2,000,000	New	+$21.7M	2.66%	15

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bain Capital Life Sciences Investors's CABA Position: Q2 2026 in Review

Bain Capital Life Sciences Investors increased its Cabaletta Bio (CABA) stake by 78% in Q2 2026, buying an estimated $24.9M and bringing the position to 17,241,445 shares worth $53.6M. The position accounts for 3.19% of the portfolio, ranked #10.

Bain Capital Life Sciences Investors first reported a position in CABA in Q2 2023 and has held it in 13 quarters since. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Bain Capital Life Sciences Investors held 17,241,445 shares of Cabaletta Bio worth $53.6M as of Q2 2026.
Bain Capital Life Sciences Investors bought 7,564,320 Cabaletta Bio shares in Q2 2026, an estimated $24.9M.
Cabaletta Bio made up 3.19% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #10 holding.
Bain Capital Life Sciences Investors first reported a position in Cabaletta Bio in Q2 2023 and has held it in 13 quarters since.
139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.